Metabolic activation and deactivation of fusarin C, a mutagen produced by Fusarium moniliforme

Insights

Fusarin C, a mutagen from Fusarium moniliforme, is activated by microsomal monooxygenase and deactivated by glutathione S-transferase. This study details the metabolic pathways of this fungal toxin.

Area of Science:

  • * Mycology
  • * Toxicology
  • * Biochemistry

Background:

  • * Fusarium moniliforme strain MRC 826 produces the mycotoxin fusarin C.
  • * Fusarin C is a known mutagen requiring metabolic activation.
  • * Understanding its metabolic fate is crucial for risk assessment.

Purpose of the Study:

  • * To investigate the metabolic activation and deactivation pathways of fusarin C.
  • * To identify the enzymes involved in fusarin C metabolism.
  • * To characterize the mutagenicity of fusarin C using a bacterial assay.

Main Methods:

  • * Salmonella typhimurium mutagenicity assay with tester strain TA 100.
  • * Use of phenobarbitone-induced microsomal monooxygenase for activation studies.
  • * Investigation of deactivation mechanisms involving thiol binding and enzymatic conjugation.

Main Results:

  • * Microsomal monooxygenase, induced by phenobarbitone, activates fusarin C to a mutagenic form.
  • * Deactivation involves chemical binding to thiol groups.
  • * Cytosolic glutathione S-transferase mediates enzymatic conjugation for detoxification.

Conclusions:

  • * Fusarin C metabolism is a two-step process involving activation and deactivation.
  • * Microsomal monooxygenase and glutathione S-transferase play key roles.
  • * The findings provide insight into the toxicological mechanisms of fusarin C.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...